Butterfly Network, Inc 8-K, filed May 1, 2024
Butterfly Network, Inc. (BFLY)
About this 8-K
Butterfly Network, Inc filed this 8-K on May 1, 2024, reporting on events of April 26, 2024.
Items reported
- Item 2.02: Financial results
- Item 3.01: Delisting notice or listing transfer
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of | (Commission File Number) | (IRS Employer |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| | |||
| |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 1, 2024, Butterfly Network, Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2024 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 hereto.
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On April 26, 2024, the Company received a notification letter (the “Notice”) from the New York Stock Exchange (the “NYSE”) advising that because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period, it is not in compliance with Section 802.01C of the NYSE Listed Company Manual (“Section 802.01C”). The Company’s common stock will continue to be listed and traded on the NYSE, subject to the Company’s compliance with other NYSE continued listing standards.
Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum price criteria. The Company will notify the NYSE within 10 business days of its receipt of the Notice of its intent to cure the deficiency. The Company may regain compliance with the minimum price criteria at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. The Company intends to consider all available alternatives to regain compliance within the six-month cure period and will pursue those alternatives that are in the best interest of the Company and its shareholders.
The Notice does not affect the ongoing business operations of the Company or its reporting requirements with the Securities and Exchange Commission.
As required by Section 802.01C, the Company issued a press release on May 1, 2024, along with its results of operations announcing that it had received the Notice. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibits. |
Exhibit No. |
| Description |
99.1 |
| |
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Forward-Looking Statements
Certain statements, estimates, targets and projections in this Current Report on Form 8-K may constitute “forward-looking statements” within the meaning of the federal securities laws. The words “anticipate,” “believe,” continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding the Company’s or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. the Company gives no assurance that any expectations set forth in this Current Report on Form 8-K will be achieved. Various risks and uncertainties (some of which are beyond the Company’s control) or other factors could cause actual future results, performance or events to differ materially from those described herein. Some of the factors that may impact future results and performance may include, without limitation: the Company’s ability to regain compliance with the continued listing standards of the NYSE within the applicable cure period, the Company’s ability to continue to comply with applicable listing standards of the NYSE, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and in other filings that the Company makes with the Securities and Exchange Commission. These filings address other important risks and uncertainties that could cause actual results and events to differ materially from those contained in the forward-looking statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| BUTTERFLY NETWORK, INC. | |
| | | |
| | | |
| | By: | /s/ Heather C. Getz, CPA |
| | Name: | Heather C. Getz, CPA |
| | Title: | Executive Vice President and Chief Financial & Operations Officer |
| | | |
Date: May 1, 2024 | | | |
Exhibit 99.1
Butterfly Network Reports First Quarter 2024 Financial Results
Achieves 14% Revenue Growth - Exceeding Expectations
Raises Full Year Guidance
| ● | Delivered record first quarter Revenue of $17.7 million |
| ● | Reduced Net Loss by 35% and Net Cash Used in Operations by 52% |
| ● | Successfully launched next generation device Butterfly iQ3™ and training app ScanLab™ |
| ● | Received European Union Medical Device Regulation (EU MDR) certification |
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE) -- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
Joseph DeVivo, Butterfly’s Chairman and CEO said, “We achieved our strongest first quarter in Butterfly’s history with all channels contributing. Our business returned to growth with a 22% increase in probe volume following the successful commercial launch of our third-generation handheld system, Butterfly iQ3™, which was available for only half of the quarter in the US market. Revenue increased 14% over last year’s first quarter while we improved our execution and increased efficiency across our operations, leading to a reduction in our quarterly use of cash by half. These results came on the heels of us over-achieving our fourth quarter 2023 expectations. We are so encouraged by our first quarter results that we are confidently increasing our guidance for 2024.
DeVivo continued, “Building on this progress, we recently received EU MDR certification, which will enable Butterfly to roll-out a number of advanced features on our Butterfly iQ+™ in the European market, as we continue to progress towards launching the iQ3 in Canada and Europe in 2024. Our success is also supported by the launch of our new AI-powered educational application ScanLab™, which complements Butterfly’s full suite of educational products and helps drive adoption, further fueling growth. And finally, Butterfly Garden, our partnership ecosystem enabling third-party AI development on our platform, recognized the first successful commercialization of a product developed using our technology.
“We had a number of positive announcements, a successful product launch, and reached important milestones this quarter. Our work strengthened our position as the leading point-of-care ultrasound company, and we look forward to building on our strong start throughout 2024.”
Recent Operational Highlights:
| ● | Received FDA Clearance for and Launches Next-Generation Butterfly iQ3™: On February 13, 2024, Butterfly announced the commercial launch of its third-generation handheld point-of-care ultrasound system, Butterfly iQ3, which received FDA clearance ahead of schedule in January 2024. |
| ● | Received EU MDR Certification for Butterfly iQ+: On March 20, 2024, Butterfly announced the attainment of its EU MDR certificate for the Butterfly iQ+ ultrasound system. This additional certification allows Butterfly to release important new features to all existing and prospective European customers, including Pulse Wave Doppler in a number of presets and its AI-enabled Auto B-Line Counter. |
| ● | Published White Paper on iQ Slice™ and iQ™ Fan: the paper proposed new clinical protocols using the advanced automated tools to reduce the number of scans needed in an exam and enhance diagnostic efficiency. It can be accessed at: https://www.butterflynetwork.com/resources. |
| ● | Launched Ultrasound Education Offering ScanLab™: On January 15, 2024, Butterfly launched Scanlab™, an AI-powered educational application for ultrasound scanning practice that joins Butterfly’s full suite of education products. |
| ● | First Butterfly Garden Commercialization: On April 23, 2024, ThinkSono released ThinkSono AI Training and became Butterfly’s first partner in Butterfly Garden to commercialize an offering. |
| ● | Hosted Investor Day: On March 18, 2024, Butterfly hosted an Investor Day at the New York Stock Exchange that featured presentations from members of Butterfly’s executive and senior leadership team, providing insights into the Company’s product, software and services portfolio within its core point-of-care ultrasound market, as well as its strategic initiatives to expand into new markets. A replay of the event can be accessed under Archived Events at: https://ir.butterflynetwork.com/events-and-presentations/default.aspx |
Three Months Ended March 31, 2024 Financial Results
Revenue: Total revenue was $17.7 million, up from $15.5 million in the first quarter of 2023. U.S. revenue was $12.2 million, up 19% from prior year, driven by the launch of iQ3, higher probe sales and higher average selling prices. International sales increased 14% year-over-year to $4.2 million, primarily due to higher probe volume partially offset by lower average selling prices due to a higher mix of sales to distributors. Other revenue contributed $1.3 million.
| ● | Product revenue was $11.3 million, an increase of 28% versus the prior year period, driven by the 22% increase in units fulfilled year-over-year. |
| ● | Software and other services revenue was down 4% year-over-year at $6.4 million. Software and services mix was 36% of revenue and decreased by 7 percentage points versus prior year due to the higher product revenue achieved this quarter. |
Gross profit: Gross profit was $10.3 million versus gross profit of $9.1 million in the prior year period. Gross margin decreased to 58.2% from 58.7% in the prior year period, primarily due to product mix, reflecting a higher proportion of product revenues, and higher amortization which reduced margin by approximately 170 basis points, partially offset by higher average selling prices.
Operating expenses: Operating expenses were $32.9 million, down 25% from $44.1 million in the prior year period, due to previously announced reductions in force, as well as non-payroll spending rationalization across all areas.
Total operating expenses excluding stock-based compensation and Other expense were $26.0 million, compared to $33.5 million in the first quarter of 2023, representing a decrease of 22%.
Net loss: Net loss was $21.8 million, compared to $33.5 million in the prior year period.
Adjusted EBITDA: Adjusted EBITDA loss was $13.2 million, compared to $22.3 million in the prior year period.
Adjusted EPS: Adjusted EPS was ($0.07), compared to ($0.11) in the prior year period.
Cash, cash equivalents, and restricted cash: Cash, cash equivalents, and restricted cash were $116.8 million as of March 31, 2024.
Guidance
Increased guidance for the Fiscal Year 2024 to:
| ● | $75 million to $80 million or approximately 15-20% Revenue growth |
| ● | Adjusted EBITDA loss of $55 million - $50 million |
A reconciliation of net loss to adjusted EBITDA and adjusted EPS for the three months ended March 31, 2024, and 2023 is provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Non-GAAP Financial Measures.”
NYSE Listing Standards
On April 26, 2024, we received a notification letter from the New York Stock Exchange (the “NYSE”) advising us that because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period, we are not in compliance the NYSE listing standards. The Company’s common stock will continue to be listed and traded on the NYSE, subject to our compliance with other NYSE continued listing standards.
Butterfly has a period of six months following the receipt of the notification to regain compliance with the minimum price criteria. The Company plans to regain compliance through a recovery in the stock price and, if the stock price does not recover within the applicable cure period, through a reverse stock split. The Delisting Notice does not affect the ongoing business operations of the Company or its reporting requirements with the Securities and Exchange Commission.
Conference Call
A conference call and webcast to discuss first quarter 2024 financial results and operational progress is scheduled for 5:00 pm ET on May 1, 2024. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on their telephone may do so by dialing in approximately ten minutes prior to start time:
US domestic callers: +1 (833) 470-1428
Global Dial-In Numbers:
https://www.netroadshow.com/events/global-numbers?confId=63404
Access Code: 497756
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission is to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas,
CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.
Non-GAAP Financial Measures
In addition to providing financial measures based on generally accepted accounting principles in the United States of America (“GAAP”), we provide additional financial measures that are not prepared in accordance with GAAP (“non-GAAP”). The non-GAAP financial measures included in this press release are adjusted EBITDA and adjusted EPS. We present non-GAAP financial measures in order to assist readers of our financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures provide an additional tool for investors to use in comparing our financial performance over multiple periods.
Adjusted EBITDA and adjusted EPS are key performance measures that our management uses to assess our operating performance. These non-GAAP measures facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that adjusted EBITDA and adjusted EPS enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.
Adjusted EBITDA and adjusted EPS may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. Adjusted EBITDA and adjusted EPS are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating the Company’s performance, you should consider adjusted EBITDA and adjusted EPS alongside other financial performance measures prepared in accordance with GAAP, including net loss and EPS.
The non-GAAP financial measures do not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. In this press release, we have provided reconciliations of adjusted EBITDA and adjusted EPS to net loss, the most directly comparable GAAP financial measures. Reconciliations of adjusted EBITDA and adjusted EPS to corresponding GAAP measures are not available on a forward-looking basis because we are unable to predict with reasonable certainty the non-cash component of employee compensation expense, changes in our working capital needs, variances in our supply chain, the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our expectations with respect to financial results, future performance, commercialization and plans to deploy our products and services, development of products and services, the size and potential growth of current or future markets for our products and services and expectations of regaining compliance with the NYSE listing requirements. Forward-looking statements are based on our current beliefs and assumptions and on information currently available to us. These forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Factors that may cause such differences include, but are not limited to: our ability to grow and manage growth effectively; the success, cost, and timing of our product and service development activities; the potential attributes and benefits of our products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any approved product; our ability to identify, in-license, or acquire additional technology; our ability to maintain our existing license, manufacturing, supply, and distribution agreements; our ability to compete with other companies currently marketing or engaged in the development of products and services that we are currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others; the pricing of our products and services, and reimbursement for medical procedures conducted using our products and services; our estimates regarding expenses, revenue, capital requirements, and needs for additional financing; our financial performance; our ability to raise financing in the future; and other risks and uncertainties indicated from time to time in our most recent Annual Report on Form 10-K, as amended, or in subsequent filings that we make with the Securities and Exchange Commission. We caution that the foregoing list of factors is not exclusive. We caution you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. We do not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based.
Contacts:
Investors
Heather Getz
Chief Financial and Operations Officer, Butterfly
hgetz@butterflynetinc.com
Neal Nagarajan
IR Agency Representative, Sloane & Company
(301) 273-5662
nnagarajan@sloanepr.com
BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(Unaudited)
| | Three months ended March 31, | ||||
|
| 2024 |
| 2023 | ||
Revenue: | | |
| | |
|
Product | | $ | 11,291 | | $ | 8,848 |
Software and other services | |
| 6,365 | |
| 6,628 |
Total revenue | | | 17,656 | | | 15,476 |
Cost of revenue: | | |
| | |
|
Product | | | 5,096 | | | 4,349 |
Software and other services | | | 2,284 | | | 2,038 |
Total cost of revenue | | | 7,380 | | | 6,387 |
Gross profit | | | 10,276 | | | 9,089 |
Operating expenses: | | | | | | |
Research and development | | | 10,720 | | | 16,651 |
Sales and marketing | | | 10,378 | | | 10,034 |
General and administrative | | | 10,442 | | | 11,019 |
Other | | | 1,357 | | | 6,432 |
Total operating expenses | | | 32,897 | | | 44,136 |
Loss from operations | | | (22,621) | | | (35,047) |
Interest income | | | 1,511 | | | 1,784 |
Interest expense | | | (300) | | | — |
Change in fair value of warrant liabilities | | | (207) | | | (207) |
Other (expense) income, net | | | (141) | | | 17 |
Loss before provision for income taxes | | | (21,758) | | | (33,453) |
Provision for income taxes | |
| 3 | |
| 87 |
Net loss and comprehensive loss | | $ | (21,761) | | $ | (33,540) |
Net loss per common share attributable to Class A and B common stockholders, basic and diluted | | $ | (0.10) | | $ | (0.17) |
Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted | | | 208,873,449 | | | 202,565,877 |
BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
|
| March 31, |
| December 31, | | ||
|
| 2024 |
| 2023 |
| ||
Assets | |
| | |
| | |
Current assets: | |
| | |
| | |
Cash and cash equivalents | | $ | 112,652 | | $ | 134,437 | |
Accounts receivable, net | |
| 13,914 | |
| 13,418 | |
Inventories | |
| 74,494 | |
| 73,022 | |
Current portion of vendor advances | | | 3,979 | | | 2,815 | |
Prepaid expenses and other current assets | |
| 8,234 | |
| 7,571 | |
Total current assets | | | 213,273 | | | 231,263 | |
Property and equipment, net | | | 24,425 | | | 25,321 | |
Intangible assets, net | | | 9,967 | | | 10,317 | |
Non-current portion of vendor advances | |
| 15,169 | |
| 15,276 | |
Operating lease assets | | | 15,325 | | | 15,675 | |
Other non-current assets | |
| 6,129 | |
| 6,422 | |
Total assets | | $ | 284,288 | | $ | 304,274 | |
Liabilities and stockholders’ equity | |
| | | | | |
Current liabilities: | |
|
| |
|
| |
Accounts payable | | $ | 5,808 | | $ | 5,090 | |
Deferred revenue, current | |
| 14,464 | |
| 15,625 | |
Accrued purchase commitments, current | |
| 131 | |
| 131 | |
Accrued expenses and other current liabilities | | | 21,139 | | | 23,425 | |
Total current liabilities | | | 41,542 | | | 44,271 | |
Deferred revenue, non-current | | | 7,217 | | | 7,394 | |
Warrant liabilities | | | 1,033 | | | 826 | |
Operating lease liabilities | | | 22,252 | | | 22,835 | |
Other non-current liabilities | | | 8,240 | | | 8,895 | |
Total liabilities | | | 80,284 | | | 84,221 | |
Commitments and contingencies | | | | | | | |
Stockholders’ equity: | | | | | | | |
Class A common stock $.0001 par value; 600,000,000 shares authorized at March 31, 2024 and December 31, 2023; 184,214,377 and 181,221,794 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | | | 18 | | | 18 | |
Class B common stock $.0001 par value; 27,000,000 shares authorized at March 31, 2024 and December 31, 2023; 26,426,937 shares issued and outstanding at March 31, 2024 and December 31, 2023 | | | 3 | | | 3 | |
Additional paid-in capital | | | 955,382 | | | 949,670 | |
Accumulated deficit | | | (751,399) | | | (729,638) | |
Total stockholders’ equity | | | 204,004 | | | 220,053 | |
Total liabilities and stockholders’ equity | | $ | 284,288 | | $ | 304,274 | |
BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
| | Three months ended March 31, | ||||
| | 2024 | | 2023 | ||
Cash flows from operating activities: | | | | | | |
Net loss |
| $ | (21,761) |
| $ | (33,540) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | |
| |
Depreciation, amortization, and impairments | |
| 2,584 | |
| 2,111 |
Non-cash interest expense | | | 299 | | | — |
Write-down of inventories | | | (81) | | | — |
Stock-based compensation expense | | | 5,524 | | | 4,185 |
Change in fair value of warrant liabilities | | | 207 | | | 207 |
Other | | | 244 | | | (708) |
Changes in operating assets and liabilities: | |
| | | | |
Accounts receivable | | | (751) | | | 1,077 |
Inventories | |
| (1,391) | |
| (9,437) |
Prepaid expenses and other assets | | | (376) | | | (3,175) |
Vendor advances | | | (1,057) | | | 2,260 |
Accounts payable | | | 703 | | | (1,561) |
Deferred revenue | | | (1,338) | | | (1,536) |
Accrued purchase commitments | | | — | | | (1,615) |
Change in operating lease assets and liabilities | | | (163) | | | 175 |
Accrued expenses and other liabilities | | | (3,310) | | | (1,695) |
Net cash used in operating activities | | | (20,667) | | | (43,252) |
| | | | | | |
Cash flows from investing activities: | |
|
| |
|
|
Purchases of marketable securities | | | — | | | (297) |
Sales of marketable securities | | | — | | | 76,484 |
Purchases of property, equipment, and intangible assets, including capitalized software | |
| (1,138) | |
| (1,342) |
Sales of property and equipment | | | — | | | 10 |
Net cash (used in) provided by investing activities | | | (1,138) | | | 74,855 |
| |
| | |
| |
Cash flows from financing activities: | |
| | |
| |
Net cash provided by financing activities | | | — | | | — |
Net (decrease) increase in cash, cash equivalents, and restricted cash | | | (21,805) | | | 31,603 |
Cash, cash equivalents, and restricted cash, beginning of period | | | 138,650 | | | 166,828 |
Cash, cash equivalents, and restricted cash, end of period | | $ | 116,845 | | $ | 198,431 |
BUTTERFLY NETWORK, INC.
GROSS PROFIT AND GROSS MARGIN
(In thousands)
(Unaudited)
| | Three months ended March 31, | | |||||
| | 2024 | | | 2023 | | ||
Revenue |
| $ | 17,656 | | | $ | 15,476 | |
Cost of revenue | |
| 7,380 | | |
| 6,387 | |
Gross profit | | $ | 10,276 | | | $ | 9,089 | |
| | | | | | | | |
Gross margin | | | 58.2 | % | | | 58.7 | % |
| | | | | | | | |
Depreciation and amortization | | $ | 1,585 | | | $ | 1,287 | |
% of revenue | | | 9.0 | % | | | 8.3 | % |
BUTTERFLY NETWORK, INC.
ADJUSTED EBITDA
(In thousands)
(Unaudited)
| Included on the condensed consolidated statements of operations and comprehensive loss as: | | Three months ended March 31, | ||||
| | | 2024 | | 2023 | ||
Net loss | Net loss |
| $ | (21,761) |
| $ | (33,540) |
Stock-based compensation | R&D, S&M, and G&A |
| | 5,524 |
| | 4,185 |
Change in fair value of warrant liabilities | Change in fair value of warrant liabilities | | | 207 | | | 207 |
Other | Other | | | 1,357 | | | 6,432 |
Other expense (income), net | Other (expense) income, net |
| | 141 |
| | (17) |
Adjusted net loss | | | | (14,532) | | | (22,733) |
Interest income | Interest income |
| | (1,511) |
| | (1,784) |
Interest expense | Interest expense |
| | 300 |
| | — |
Provision for income taxes | Provision for income taxes |
| | 3 |
| | 87 |
Depreciation and amortization | Cost of revenue, R&D, S&M, and G&A |
| | 2,584 |
| | 2,111 |
Adjusted EBITDA | |
| $ | (13,156) |
| $ | (22,319) |
| | | | | | | |
Adjusted EPS | | | $ | (0.07) | | $ | (0.11) |
Weighted average shares used to compute adjusted EPS | | | | 208,873,449 | | | 202,565,877 |